These findings suggest that eIF4E is a logical therapeutic target for increasing tumor cell radiosensitivity and overcoming cancer radioresistance, implying that eIF4E-targeting strategies for oral cancer treatment may have clinical utility. This evidence concerns the gene EIF4E and lip and oral cavity carcinoma.